Combination therapies employing platelet aggregation drugs

Abstract

The present invention provides pharmaceutical compositions comprising a platelet aggregation inhibitor and a compound selected from pyridoxal-5'-phosphate, a pyridoxal-5'-phosphate related compound or a pharmaceutically acceptable salt thereof and methods for using a platelet aggregation inhibitor and a compound selected from pyridoxal-5'-phosphate, a pyridoxal-5'-phosphate related compound or a pharmaceutically acceptable salt thereof, for inhibiting platelet aggregation, for treating diseases that arise from prothrombotic and thrombotic states in which the coagulation cascade is activated and for reducing the risk of cardiovascular disease or cerebrovascular disease.

Description

technical field

[0001] The present invention relates to a pharmaceutical composition and its use for treating cardiovascular diseases. In particular, the invention relates to the use of combination therapy with platelet aggregation drugs. Background technique

[0002] The role of platelets in the pathophysiology of atherosclerotic disease and thrombotic events is well known. Long-term prophylactic use of antiplatelet drugs that inhibit platelet aggregation has been shown to be beneficial in preventing ischemic stroke, myocardial infarction, unstable angina, peripheral arterial disease, need for vascular bypass surgery or angioplasty, and vascular death in patients, Said patients are at increased risk of these events and include those with established atherosclerosis or a history of arterial thrombosis.

[0003] Currently, many antiplatelet drugs are widely available and their combination therapy has been and continues to be studied. Most antiplatelet drugs have side effec...

Images